Preferred Name |
Degarelix
|
Definition |
A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes./NCI-GLOSS Definition: A drug that is used to treat advanced prostate cancer and is also being studied in the treatment of benign prostatic hyperplasia. Degarelix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the body to stop making testosterone, which prostate cancer needs to grow. Degarelix is a type of GnRH antagonist.
|
Synonyms & Abbreviations |
Degarelix DEGARELIX degarelix FE200486 Firmagon N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide
|
ReferenceCode |
NCI Thesaurus Code:C48385
|
ReferenceURL |
https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C48385
|
PMID |
NA
|